Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) serves as a notification of the submission of its Annual Report on Form 20-F for the fiscal year ended 31 December 2017. The filing was issued on 16 March 2018 and submitted to the SEC on 19 March 2018.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. It solely announces the availability of the audited financial statements contained within the referenced Form 20-F.
Material Changes
No material changes or comparative financial data are disclosed in this specific document. The filing directs investors to the full Annual Report for detailed performance analysis.
Guidance, Outlook, and Risks
- Forward-Looking Statements: GSK includes a cautionary statement noting that projections are subject to risks and uncertainties that may cause actual results to differ materially.
- Risk Factors: Specific risks are referenced under Item 3.D "Risk factors" in the 2017 Annual Report on Form 20-F but are not detailed in this summary.
- Shareholder Information: Hard copies of the 2017 Annual Report and Notice of Annual General Meeting were expected to be available on or about 29 March 2018.
Investor Verification Checklist
- Verify the audited financial statements for the year ended 31 December 2017 in the full Form 20-F available at www.gsk.com/corporatereporting or www.sec.gov.
- Review Item 3.D "Risk factors" in the 2017 Annual Report for detailed risk disclosures.
- Confirm the date and details of the Annual General Meeting via the Notice of Annual General Meeting.
- Check for any subsequent updates or earnings releases issued after the 16 March 2018 announcement date.